• Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

    Source: Nasdaq GlobeNewswire / 02 May 2024 16:05:00   America/New_York

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

    Conference Call & Webcast

    Thursday, May 9th @ 4:30 PM ET
    Domestic:1-888-886-7786
    International:1-416-764-8658
    Conference ID: 71864759
      

    Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.

    Call me™: https://emportal.ink/3xjDV8X

    Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1664624&tp_key=4756f5f4c0

    About Crinetics Pharmaceuticals 
    Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, first-in-class, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.

    Contact:
    Corey Davis
    LifeSci Advisors, LLC
    cdavis@lifesciadvisors.com
    (212) 915-2577

    Media:
    Natalie Badillo
    Head of Corporate Communications
    nbadillo@crinetics.com
    858 345-6075

    Source: Crinetics Pharmaceuticals, Inc.


    Primary Logo

Share on,